论文部分内容阅读
目的探究血清促卵泡素(FSH)、黄体生成素(LH)以及垂体泌乳素(PRL)等性激素的表达水平与女性闭经后萎缩性尿道炎患者疾患之间的关系。方法以52例女性闭经后萎缩性尿道炎患者为实验组,52例月经正常女性为对照组,两组均使用放射免疫法来检测血清FSH、LH以及PRL等性激素的表达水平并进行对比,确定其在女性闭经后萎缩性尿道炎患者中的应用价值。结果实验组血清FSH含量为(11.81±12.95)mu/ml、LH含量为(12.24±10.00)mu/ml以及PRL含量为(39.11±31.64)ng/ml;对照组血清FSH含量为(6.61±2.51)mu/ml、LH含量为(4.53±3.51)mu/ml以及PRL含量为(14.49±5.36)ng/ml,两组差异均有统计学意义(P<0.05)。实验组E2含量为(42.09±15.35)pg/ml、P含量为(0.55±0.20)ng/ml以及T含量为(0.33±0.12)ng/ml,对照组E2含量为(51.67±8.95)pg/ml、P含量为(0.54±0.23)ng/ml以及T含量为(0.32±0.10)ng/ml,两组E2差异有统计学意义(P<0.05)。结论女性血清FSH、LH以及PRL等性激素的表达水平与其闭经后萎缩性尿道炎之间存在密切关系,可以有效体现闭经后萎缩性尿道炎患者的身体情况,可用于预防闭经后萎缩性尿道炎,值得临床诊治参考。
Objective To investigate the relationship between the expression of sex hormones such as serum follicle stimulating hormone (FSH), luteinizing hormone (LH) and pituitary prolactin (PRL) and the diseases of women with atrophic urethritis after amenorrhea. Methods Fifty-two women with post-menopausal atrophic urethritis were selected as experimental group and 52 normal menstruation women as control group. Radioimmunoassay was used to detect the expression of FSH, LH and PRL and other sex hormones in both groups. Its value in women with atrophic urethritis after amenorrhea. Results The FSH content in the experimental group was (11.81 ± 12.95) mu / ml, the LH content was (12.24 ± 10.00) mu / ml and the PRL content was (39.11 ± 31.64) ng / ) mu / ml, LH content (4.53 ± 3.51) mu / ml and PRL content (14.49 ± 5.36) ng / ml respectively. There was significant difference between the two groups (P <0.05). The content of E2 in experimental group was (42.09 ± 15.35) pg / ml, the content of P was 0.55 ± 0.20 ng / ml and the content of T was 0.33 ± 0.12 ng / ml in control group and 51.67 ± 8.95 pg / ml, the content of P was (0.54 ± 0.23) ng / ml and the content of T was (0.32 ± 0.10) ng / ml, there was significant difference between the two groups (P <0.05). Conclusion There is a close relationship between the expression of FSH, LH, PRL and other sex hormones in female patients with atrophic urethritis after amenorrhea, which can effectively reflect the physical condition of patients with atrophic urethritis after menopause and can be used to prevent postmenopausal atrophic urethritis, Worthy of clinical diagnosis and treatment.